Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)

Launched by INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL, CHINA · Oct 24, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a rare childhood disease called primary immune thrombocytopenia (ITP). In ITP, the body mistakenly destroys its own platelets, which are important for blood clotting. The goal of this study is to gather detailed information about how ITP affects children in China, the treatments that work best, and what the future might look like for these patients. Researchers hope to learn more about the disease and create a helpful model for predicting outcomes.

The study is open to boys and girls aged 6 to 17 who have been diagnosed with ITP. However, children with other conditions that cause low platelet counts, like certain cancers or blood disorders, will not be included. Participants can expect to be followed for at least three months, during which their health and treatment responses will be closely monitored. This research is important because it aims to provide a better understanding of ITP in children and improve care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 6-17 years old (including both ends), male and female;
• • Diagnosis of ITP.
• Exclusion Criteria:
• • Secondary thrombocytopenia caused by various reasons, such as connective tissue disorders, bone marrow hematopoietic failure disease, myelodysplastic syndrome, malignancy, drugs, inherited thrombocytopenia, common variable immune deficiency, lymphoma, etc.;
• • The expected follow-up period is less than 3 months.